Public Demand for Petrol and Diesel Crashes in June 2026

Pakistan's oil marketing companies (OMCs) recorded a sharp decline in petroleum sales during June 2026, with total sales ...

J&J or AbbVie: Which Stock Deserves a Place in Your Portfolio Now?

JNJ and ABBV both offer solid long-term growth potential, but differences in diversification, pipeline strength and estimates ...
International Railway Journal

German Rhineland S-Bahn pre-tender notice

Rhine-Ruhr Transport (VRR) and go.Rheinland have released information on the Rhineland Stage 2 S-Bahn contract in ...

J&J Stock Down 3% in 3 Months: Is the Dip a Buying Opportunity?

J&J's shares fall 3% in three months despite solid results and pipeline progress, raising questions about whether the pullback is a buying opportunity.
Interfax-Ukraine

Ukraine needs to rethink Ukrzaliznytsia's business model and index freight rates – EBRD

Ukrzaliznytsia’s business model, which relied on cross-subsidizing passenger transport with freight revenue without state ...

Takeda's Zasocitinib Achieved Significantly Greater Complete Skin Clearance Than Deucravacitinib in Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Ex…

CNW/ - Takeda Canada Inc. ("Takeda") is pleased to announce positive topline results for the Phase 3, randomized, multicenter ...

Oruka Therapeutics' Head of Finance Sold Over 10,000 Company Shares. What Does That Mean for Investors?

Detailed price information for Oruka Therapeutics Inc (ORKA-Q) from The Globe and Mail including charting and trades.
Seeking Alpha

AbbVie: Maintaining My Strong Buy Rating After Label Expansion

The last time I spoke about AbbVie (ABBV), it was with a Seeking Alpha article entitled "AbbVie: Double-Digit Growth For Immunology Products Continues With HUMIRA Surprise." With respect to this ...